These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 36349778)

  • 41. Giving weight to incretin-based pharmacotherapy for obesity-related sleep apnea: a revolution or a pipe dream?
    Grunstein RR; Wadden TA; Chapman JL; Malhotra A; Phillips CL
    Sleep; 2023 Oct; 46(10):. PubMed ID: 37668448
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems.
    Seufert J; Gallwitz B
    Diabetes Obes Metab; 2014 Aug; 16(8):673-88. PubMed ID: 24373150
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Harnessing the weight-regulating properties of glucagon-like peptide-1 in the treatment of type 2 diabetes.
    Sesti G
    Diabetes Obes Metab; 2009 Dec; 11 Suppl 3():4-10. PubMed ID: 19878256
    [TBL] [Abstract][Full Text] [Related]  

  • 44. American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD).
    Cusi K; Isaacs S; Barb D; Basu R; Caprio S; Garvey WT; Kashyap S; Mechanick JI; Mouzaki M; Nadolsky K; Rinella ME; Vos MB; Younossi Z
    Endocr Pract; 2022 May; 28(5):528-562. PubMed ID: 35569886
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Slow and Steady Wins the Race: 25 Years Developing the GLP-1 Receptor as an Effective Target for Weight Loss.
    Kumar N; D'Alessio DA
    J Clin Endocrinol Metab; 2022 Jul; 107(8):2148-2153. PubMed ID: 35536590
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Glucagon-like peptide 1 receptor agonists in type 1 diabetes mellitus.
    Guyton J; Jeon M; Brooks A
    Am J Health Syst Pharm; 2019 Oct; 76(21):1739-1748. PubMed ID: 31612934
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Pharmacological therapy of obesity].
    Pagotto U; Vanuzzo D; Vicennati V; Pasquali R
    G Ital Cardiol (Rome); 2008 Apr; 9(4 Suppl 1):83S-93S. PubMed ID: 18773755
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effect of semaglutide on liver enzymes and markers of inflammation in subjects with type 2 diabetes and/or obesity.
    Newsome P; Francque S; Harrison S; Ratziu V; Van Gaal L; Calanna S; Hansen M; Linder M; Sanyal A
    Aliment Pharmacol Ther; 2019 Jul; 50(2):193-203. PubMed ID: 31246368
    [TBL] [Abstract][Full Text] [Related]  

  • 49. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY.
    Garvey WT; Mechanick JI; Brett EM; Garber AJ; Hurley DL; Jastreboff AM; Nadolsky K; Pessah-Pollack R; Plodkowski R;
    Endocr Pract; 2016 Jul; 22 Suppl 3():1-203. PubMed ID: 27219496
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Beinaglutide shows significantly beneficial effects in diabetes/obesity-induced nonalcoholic steatohepatitis in ob/ob mouse model.
    Fang X; Du Z; Duan C; Zhan S; Wang T; Zhu M; Shi J; Meng J; Zhang X; Yang M; Zuo Y
    Life Sci; 2021 Apr; 270():118966. PubMed ID: 33482185
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Comparison of the Efficacy of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Metabolic Associated Fatty Liver Disease: Updated Systematic Review and Meta-Analysis.
    Dai Y; He H; Li S; Yang L; Wang X; Liu Z; An Z
    Front Endocrinol (Lausanne); 2020; 11():622589. PubMed ID: 33664710
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Incretin therapy for diabetes mellitus type 2.
    Holst JJ
    Curr Opin Endocrinol Diabetes Obes; 2020 Feb; 27(1):2-10. PubMed ID: 31815785
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Glucagon-like peptide-1 receptor agonists to expand the healthy lifespan: Current and future potentials.
    Kreiner FF; von Scholten BJ; Kurtzhals P; Gough SCL
    Aging Cell; 2023 May; 22(5):e13818. PubMed ID: 37191234
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Potential roles of glucagon-like peptide-1-based therapies in treating non-alcoholic fatty liver disease.
    Liu Y; Wei R; Hong TP
    World J Gastroenterol; 2014 Jul; 20(27):9090-7. PubMed ID: 25083081
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Therapeutic options that provide glycemic control and weight loss for patients with type 2 diabetes.
    Blevins T
    Postgrad Med; 2010 Jan; 122(1):172-83. PubMed ID: 20107301
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy and safety of semaglutide for weight management: evidence from the STEP program.
    Amaro A; Sugimoto D; Wharton S
    Postgrad Med; 2022 Jan; 134(sup1):5-17. PubMed ID: 36691309
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Discovery of a novel GLP-1/GIP dual receptor agonist CY-5 as long-acting hypoglycemic, anti-obesity agent.
    Liu C; Li C; Cai X; Zou Y; Mo J; Chen B; Cai Y; Han T; Huang W; Qian H; Zhang W
    Bioorg Chem; 2021 Jan; 106():104492. PubMed ID: 33268008
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Liraglutide in the treatment of obesity.
    Ng SY; Wilding JP
    Expert Opin Biol Ther; 2014 Aug; 14(8):1215-24. PubMed ID: 24905058
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The cardiovascular effects of novel weight loss therapies.
    Usman MS; Davies M; Hall ME; Verma S; Anker SD; Rosenstock J; Butler J
    Eur Heart J; 2023 Dec; 44(48):5036-5048. PubMed ID: 37966486
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Editorial: evolution of GLP-1 receptor agonists as pharmacotherapy for NASH beyond diabetes mellitus and obesity.
    Kim W
    Aliment Pharmacol Ther; 2021 Dec; 54(11-12):1496-1497. PubMed ID: 34741326
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.